A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Clinical Pharmacokinetics

Volumn 53, Issue 9, 2014, Pages 787-800

  Haahr, Hanne ^a   Heise, Tim ^b  

^a NOVO NORDISK A S   (Denmark)

^b Profil   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN DEGLUDEC; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HUMAN; INJECTION SITE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEADY STATE; CHEMISTRY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; MEDICINAL CHEMISTRY; METABOLISM;

CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING;

EID: 84920991726     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0165-y     Document Type: Review

References (65)

1. Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014;20:75–83.
2. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64:1415–24.
3. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab. 2009;11:5–19.
4. Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27:632–3.
5. Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diabet Med. 2006;23:46–52.
6. Dhatariya K, Yeong J. Improved glycaemic controls for patients on twice daily dosing regime of insulin glargine compared to those on a once daily dosing regime. Diabetologia. 2010;53(suppl 1):S390.
7. Insulin glargine. Summary of product characteristics. 9 June 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf. Accessed 6 Dec 2013.
8. Insulin detemir. Summary of product characteristics. 16 April 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000528/WC500036662.pdf. Accessed 6 Dec 2013.
9. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543–5.
10. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–9.
11. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–20.
12. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290–9.
13. Unger J. Diabetes management in primary care. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
14. Coester H-V, Heise T, Nosek L, et al. Steady state is reached within 2 to 3 days of once-daily administration of ultra-long-acting insulin degludec. Diabetologia. 2012;55(suppl 1):373.
15. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54(suppl 1):S426.
16. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14.
17. Seested T, Havelund S, Jonassen I, et al. Ultrastructural visualisation of insulin degludec multi-hexamers in the subcutaneous depot in vivo supports a unique mechanism of protraction [poster no. 980P]. Diabetes. 2012;61(suppl 1):A250.
18. Steensgaard DB, Schluckebier G, Strauss HM, et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013;52:295–309.
19. Heise T, Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des. 2001;7:1303–25.
20. Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33:515–21.
21. Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944–50.
22. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–64.
23. Heise T, Hövelmann U, Nosek L, et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine [abstract]. Diabetologia. 2011;54(suppl 1):S425.
24. Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging. 2014;31:47–53.
25. Hompesch M, Morrow L, Watkins E, et al. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, White, and Hispanic/Latino patients with type 2 diabetes mellitus. Clin Ther. 2014;36:507–15.
26. Nosek L, Coester HV, Roepstorff C, Thomsen HF, Kristensen NR, Haahr H, Heise T. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. Clin Drug Investig. 2014;34:673–9.
27. Kupčová V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014;34:127–33.
28. Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53:175–83.
29. Biester T, Blaesig S, Remus K, et al. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2014;15:27–33.
30. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics—concepts and applications. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
31. ® product information. Novo Nordisk Pharma Ltd. September 2012 [in Japanese]. http://www.info.pmda.go.jp/go/pack/2492419G1021_1_03/. Accessed 25 Apr 2014.
32. Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13:677–84.
33. Korsatko S, Deller S, Mader J et al. Ultra-long pharmacokinetic properties of insulin degludec in younger adults are preserved in geriatric subjects with type 1 diabetes [abstract no. 1316]. American Association of Clinical Endocrinologists, Inc., 21st Annual Scientific and Clinical Congress; 23–27 May 2012; Philadelphia.
34. Haahr H, Ikushima I, Hirao K, et al. Similar pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese and Caucasian subjects with T1DM [abstract no. PCS-16-6]. J Diabetes Investig. 2012;3(suppl s1):197.
35. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.
36. FDA. Statistical approaches to establishing bioequivalence. January 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070244.pdf. Accessed 27 Jan 2014.
37. EMA: Committee for Medical Products for Human use (CHMP) CPMP/EWP/QWP/1401/98 Rev. 1—Guideline on the investigation of bioequivalence. 20 January 2010. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 23 Apr 2014.
38. Heise T, Nosek L, Hovelmann U, Bottcher SG, Hastrup H, Haahr H. Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect [abstract]. Diabetes. 2012;61(suppl 1):A91.
39. Danne T, Lüpke K, Walte K, et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003;26:3087–92.
40. Thalange N, Deeb LC, Iotova V, et al. Long-term efficacy and safety of insulin degludec in combination with bolus insulin aspart in children and adolescents with type 1 diabetes. Diabetologia. In Press.
41. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10:811–23.
42. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–70.
43. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9:529–50.
44. Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4:366–76.
45. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16:1592–7.
46. EMEA. Levemir: EPAR—scientific discussion. 2004. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000528/WC500036658.pdf. Accessed 5 Mar 2014.
47. Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827–35.
48. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97.
49. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–62.
50. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464–71.
51. Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36:2536–42.
52. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498–507.
53. Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858–64.
54. Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4:605–12.
55. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175–84.
56. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycaemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522–8.
57. Leiter L, Yale JF, Chaisson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on hypoglycemia management and glucose control management. Can J Diabetes. 2005;29:186–92.
58. Koehler G, Heller S, Korsatko S, et al. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia. 2014;57:40–9.
59. Younk LM, Mikeladze M, Tate D, Davis SN. Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab. 2011;6:93–108.
60. Heise T, Zijlstra E, Nosek L, Bracken R, Haahr HL, Roepstorff C, et al. Similar risk of exercise-related hypoglycaemia for insulin degludec compared to insluin glargine in patients with type 1 diabetes [poster no. PD-0791]. World Diabetes Congress; 2–6 Dec 2013; Melbourne.
61. Oyer DS, Heller S, Gough SCL, et al. Exercise-related hypoglycaemia occurs at similar frequency with insulin degludec and insulin glargine [abstract]. Diabetologia. 2013;56(suppl 1):S84.
62. Rendell M. Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs Today (Barc). 2013;49:687–97.
63. Novo Nordisk A/S. A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE). US National Institutes of Health [ClinicalTrials.gov identifier NCT01959529]. http://clinicaltrials.gov. Accessed 11 Aug 2014.
64. Josse RG, Woo V. Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin. Diabetes Obes Metab. 2013;15:1077–84.
65. Novo Nordisk A/S. A trial investigating the safety, tolerability, and distribution and activity in the body of NNC0148-0000-0287 injected under the skin in healthy subjects and in subjects with type 1 diabetes. US National Institutes of Health [ClinicalTrials.gov identifier NCT01730014]. http://clinicaltrials.gov. Accessed 11 Aug 2014.